vTv Therapeutics A

vTv Therapeutics expanded its agreement with Newsoara Biopharma, granting Newsoara exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. vTv receives $20 million upfront, up to $115 million in development and sales milestones and tiered royalties, while Newsoara advances the asset globally. The cash infusion lets vTv prioritize its Phase 3 diabetes candidate cadisegliatin while retaining long-term upside from HPP737 royalties and milestones. » Plus sur finance.yahoo.com

vTv Therapeutics has submitted the protocol for a phase-2 study of Cadisegliatin as an add-on therapy to insulin for type 2 diabetes to the Abu Dhabi Department of Health. The 12-month, randomized study of about 300 insulin-dependent patients in the UAE, Jordan and Tunisia will compare once-daily 400 mg and 800 mg Cadisegliatin with placebo; first patient visit is expected in Q1 2026. vTv will act as regulatory sponsor and M42 will fund the study; Cadisegliatin is an orally available, liver-selective glucokinase activator with FDA Breakthrough Therapy designation and is being studied in a parallel phase-3 trial for type 1 diabetes. The stock has risen nearly 150% year-to-date, valuing the company at about $446 million. » Plus sur de.investing.com

vTv Therapeutics appoints four new members to its scientific advisory board to support the clinical development of cadisegliatin, an oral Phase 3 investigational therapy for type 1 diabetes. The company emphasizes the experts’ importance for study design, clinical planning and regulatory strategy; cadisegliatin has shown good tolerability in studies to date and received FDA "Breakthrough Therapy" status. Separately, the start of the Phase 3 CATT1 study was announced with the randomization of the first participant. Financial analyses highlight a strong cash position but note continued lack of profitability; analyst price targets are $35–36, and the next quarterly report is expected on November 12, 2025. » Plus sur de.investing.com